127 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
25 Oct 22
Adaptimmune Enhances its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
8:10am
are amongst the best-characterized and validated TCR T-cell targets in the solid tumor field. With full ownership of these affinity enhanced SPEAR T … -cells against each of these targets, we will be able to bring the benefits of cell therapy to an even larger number of people with cancer,” said
8-K
EX-99.2
zdp9hwm6
10 Apr 17
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
12:00am
8-K
fpyiryhu3jy2wa xu0
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
8nhjl3l
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-99.1
137af3i 9wexhbo8
2 May 19
Other Events
7:10am
8-K
EX-99.1
7vw477ji1g945j1f3l
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
DRS
EX-10.11
wlweri
5 Feb 15
Draft registration statement
12:00am
8-K
EX-99.1
y0y7 ir2m5f
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
4ckcgg8qbs9y2qmq
24 Jul 18
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
7:36am